“Updates for Antares Pharma, Teva, AVI, NeoStem” (American Chronicle)
“New Technology Helps Parkinson’s Patients Speak Louder” (Science)
“Twitter and Health Care: Can A Tweet A Day Keep The Doctor Away?” (Science)
“CANCER: Studies from J.V. Pergolizzi et al provide new data on cancer” (Cancer Weekly)
“Generics versus Brands: Questions About Quality Control” (MedPage Today)
“Bristol-Myers Squibb Completes Initial Tender Offer for Medarex, Inc. with 87.7% of Shares Tendered; Announces Subsequent Offering Period” (Business Wire)
“Feds Chase Down Faulty Skincare Promos” (PharmExec)
“Data on asthma published by C.M. Blanchette and colleagues” (NewsRX.com)
“Walgreen to Provide Drugs to Caterpillar” (Wall Street Journal)
“Performance Of New, More Sensitive Troponin Assays ‘Excellent’” (Elsevier Global Medical News)
The diagnostic performance of the new generation of more sensitive cardiac troponin assays is excellent, according to two reports in the Aug. 27 issue of the New England Journal of Medicine.
This is copyright protected information, to receive the full article, please click here to sign up and register.
“Dainippon’s Phase III Trial Shows Lurasidone Advantage Over Placebo, But Not Against Zyprexa” (The Pink Sheet)
Dainippon Sumitoma Pharma Co. does have enough positive pivotal trials for its planned 2010 NDA filing for the atypical antipsychotic lurasidone, but the newly released data from one of those trials reveal a discrepancy in the efficacy results that could be a hurdle at FDA.
This is copyright protected information, to receive the full article, please click here to sign up and register.
“FDA May Impose More ‘522’ Studies As Post-Approval Enforcement Tool” (The Gray Sheet)
FDA says it will more frequently use its authority to mandate so-called Section 522 post-market studies when companies fail to meet their original post-approval study requirements – and this time, the idea might actually stick…
This is copyright protected information, to receive the full article, please click here to sign up and register.
“Loss of Senator Kennedy Leaves Hole In HELP Committee, Health Agenda” (The Tan Sheet)
The passing of Sen. Ted Kennedy deprives the Senate of one of its most prolific figures in the area of health legislation and leaves open the chairmanship of the committee with FDA oversight…
This is copyright protected information, to receive the full article, please click here to sign up and register.
“U.S. healthcare debate loses champion in Kennedy” (Reuters)
“J&J Wins Appeal Reviving Patent on Ultracet Drug” (Bloomberg.com)
SUBSCRIBE